(Q56965677)

11

object named as

Juliane Schwille-Kiuntke

0 references

Paul Enck

1

object named as

Paul Enck

0 references

Magnus Simrén

12

object named as

Magnus Simren

0 references

author name string

Qasim Aziz

2

0 references

Giovanni Barbara

3

0 references

Adam D Farmer

4

0 references

Shin Fukudo

5

0 references

Emeran A Mayer

6

0 references

Beate Niesler

7

0 references

Eamonn M M Quigley

8

0 references

Mirjana Rajilić-Stojanović

9

0 references

Stephan Zipfel

13

0 references

Robin C Spiller

Nature Reviews Disease Primers

14

0 references

language of work or name

English

0 references

publication date

24 March 2016

0 references

published in

0 references

volume

2

0 references

page(s)

16014

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrdp.2016.14

0 references

cites work

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Comorbidity in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable bowel syndrome and chronic pelvic pain: a singular or two different clinical syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Mood and Anxiety Disorders in Chronic Fatigue Syndrome, Fibromyalgia, and Irritable Bowel Syndrome: Results From the LifeLines Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Assessing the New DSM-5 Diagnosis of Somatic Symptom Disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Management of functional somatic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Life course study of the etiology of self-reported irritable bowel syndrome in the 1958 British birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Familial aggregation of irritable bowel syndrome: a family case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Co-occurrence of IBS and symptoms of anxiety or depression, among Norwegian twins, is influenced by both heredity and intrauterine growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Psychosocial mechanisms for the transmission of somatic symptoms from parents to children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Post-infectious irritable bowel syndrome--a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Intestinal permeability--a new target for disease prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Inflammatory bowel disease and irritable bowel syndrome: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The immune system in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Randomised controlled trial of mesalazine in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Role for protease activity in visceral pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The human microbiome project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Intestinal microbiota in functional bowel disorders: a Rome foundation report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Long-term monitoring of the human intestinal microbiota composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diet rapidly and reproducibly alters the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Review article: the role of butyrate on colonic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Inflammation as a basis for functional GI disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Is irritable bowel syndrome a low-grade inflammatory bowel disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The first 1000 cultured species of the human gastrointestinal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp. nov., isolated from human faeces

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Abnormal colonic fermentation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Fasting and postprandial volumes of the undisturbed colon: normal values and changes in diarrhea-predominant irritable bowel syndrome measured using serial MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Methanogens in Human Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The degree of breath methane production in IBS correlates with the severity of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Function of the microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Hydrogen sulfide and colonic epithelial metabolism: implications for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Serotonin and GI clinical disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Functional GI disorders: from animal models to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Peripheral mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The intestinal barrier and its regulation by neuroimmune factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Stress system--organization, physiology and immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Brain-gut microbiome interactions and functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Towards a systems view of IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Pain catastrophizing and interpersonal problems: a circumplex analysis of the communal coping model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Imaging brain mechanisms in chronic visceral pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Cortical thickness correlates of pain and temperature sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Lessons learned--resolving the enigma of genetic factors in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Deciphering microRNA code in pain and inflammation: lessons from bladder pain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Towards positive diagnosis of the irritable bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The diagnostic value of a digital rectal examination compared with high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Digital rectal examination is a useful tool for identifying patients with dyssynergia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Infectious diarrhea: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Efficient diagnosis of suspected functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Methods for diagnosis of bile acid malabsorption in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Review: Management of postprandial diarrhea syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Symptomatic fructose malabsorption in irritable bowel syndrome: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Breath tests and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Why do subjects with irritable bowel syndrome seek health care for their symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diagnosis and management of IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable bowel syndrome: relations with functional, mental, and somatoform disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Acute tryptophan depletion reduces kynurenine levels: implications for treatment of impaired visuospatial memory performance in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Fructose and lactose intolerance and malabsorption testing: the relationship with symptoms in functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The Oslo definitions for coeliac disease and related terms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of hyoscine butylbromide (Buscopan®) on cholinergic pathways in the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Antidepressants in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable bowel syndrome: an integrated explanatory model for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Evidence-based clinical practice guidelines for irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The impact of irritable bowel syndrome on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Clinical determinants of health-related quality of life in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Stimulation of colonic motility by oral PEG electrolyte bowel preparation assessed by MRI: comparison of split vs single dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Cognitive behaviour therapy for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Guided self-help interventions for irritable bowel syndrome: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Identifying effective techniques within psychological treatments for irritable bowel syndrome: a meta-analysis

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Intestinal microbiota in pathophysiology and management of irritable bowel syndrome

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Irritable bowel syndrome: the role of food in pathogenesis and management

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Irritable bowel syndrome--the main recommendations

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

An evidence-based position statement on the management of irritable bowel syndrome

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Functional bowel disorders and functional abdominal pain

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Rapid isolation of Yersinia spp. from feces

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Role of the Small Bowel and Colon in Lactose-Induced Diarrhea

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5001845

Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study

2 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Genome-Wide Association Study Identifies Two Novel Genomic Regions in Irritable Bowel Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Nutrient intake in patients with irritable bowel syndrome compared with the general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Diets that differ in their FODMAP content alter the colonic luminal microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Eluxadoline for Irritable Bowel Syndrome with Diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Quality of life in persons with irritable bowel syndrome: development and validation of a new measure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Hypersensitivity to cutaneous thermal nociceptive stimuli in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.14

Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27159638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27159638